Merck announced plans to create a separate division for its cancer business, positioning its blockbuster drug Keytruda at the center of the new structure. The move comes as the U.S. drugmaker prepares for the looming patent expiry of its top-selling therapy, a development that could significantly impact future revenues. By reorganizing its operations now, Merck aims to strengthen its oncology pipeline and cushion the financial impact once Keytruda loses exclusivity.
Keytruda: The Growth Engine Facing a Patent Cliff
Keytruda is currently the world’s best-selling prescription medicine. Approved across multiple cancer indications, the immunotherapy generated more than $30 billion in 2025 alone—accounting for nearly half of Merck’s total revenue. However, key patents protecting Keytruda will begin to expire in 2028. As a result, biosimilar competition is expected to intensify, potentially eroding sales of the flagship treatment. Given this timeline, Merck’s leadership is acting early to restructure its human health business and drive the next phase of growth.
Strategic Rationale Behind the Oncology Spin-Off
Under the new structure, Merck will divide its human health segment into two focused units:
*A dedicated oncology division, housing its cancer portfolio
*A separate division for non-oncology medicines
Importantly, the restructuring does not affect the company’s animal health division. According to James Harlow, Senior Vice President at Novare Capital Management—which holds more than 100,000 Merck shares—the reorganization signals management’s intent to accelerate oncology pipeline development.
“Management must believe that having oncology organized as its own unit will help the company drive pipeline successes that can help mitigate Keytruda’s loss of exclusivity,” Harlow noted. Additionally, the split creates long-term strategic flexibility. It gives Merck the option to potentially separate or spin off one of the businesses in the future, if market conditions warrant such a move.
Analyst Perspective: Clarity, But Execution Remains Key
Analysts at Citi say the restructuring will help investors better distinguish between Merck’s mature oncology portfolio and its newer, acquisition-driven assets. However, they caution that structural change alone will not be enough. To fully offset upcoming patent pressures, Merck must also:
- *Strengthen commercial execution
- *Accelerate business development efforts
- *Deliver consistently from its late-stage pipeline
Therefore, while the reorganization improves strategic clarity, operational performance will ultimately determine success.
Building the Post-Keytruda Pipeline
Since 2021, Merck has aggressively expanded its late-stage drug pipeline to reduce dependence on Keytruda. Notably, the company signed major acquisition deals last year, including the roughly $10 billion purchases of:
- Cidara Therapeutics
- Verona Pharma
Through these deals, Merck aims to diversify its portfolio and secure future growth drivers beyond oncology. This strategy mirrors earlier portfolio reshaping efforts. In 2021, Merck spun off its women’s health and biosimilars business into a standalone company, Organon, sharpening its focus on innovative medicines.
Financial Pressures Add Urgency
The latest restructuring announcement follows Merck’s cautious 2026 financial forecast. Earlier this month, the company projected lower-than-expected sales and profits, citing looming patent expirations and intensifying generic competition for several legacy drugs. Consequently, the creation of a standalone oncology division appears both strategic and defensive. By isolating its most valuable therapeutic area, Merck hopes to drive innovation, improve accountability, and unlock long-term shareholder value.
Positioning for the Post-Patent Era
As the 2028 patent cliff approaches, Merck is proactively reshaping its structure to reduce reliance on Keytruda. The dedicated oncology unit, combined with pipeline expansion and acquisition-led growth, signals a deliberate effort to transition from blockbuster dependency to diversified innovation. As reported by reuters.com, the success of the strategy will depend on how effectively Merck converts its pipeline investments into commercially viable therapies—before biosimilar competition reshapes the oncology market.
